Company: SION
Filing Date: 2025-03-20
Form Type: 10-K
Source: 0002036042-25-000005
Chunk: 216

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-03-20
Form: 10-K
Item: Item 8
Chunk 216
---
Net loss per share, basic and diluted$(15.99)$(16.11)Weighted-average common shares outstanding, basic and diluted3,858,8592,933,218Comprehensive loss:Net loss$(61,688)$(47,263)Other comprehensive income:Unrealized gain on marketable securities368 16 Comprehensive loss$(61,320)$(47,247)

The accompanying notes are an integral part of these consolidated financial statements. 

F-4

SIONNA THERAPEUTICS, INC. 

CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT 

(in thousands, except share amounts) 

Series Seed Series A Series B Series CAdditionalPaid-InCapitalAccumulatedOtherComprehensiveIncome (Loss)AccumulatedDeficit TotalStockholders’Deficit Preferred Stock Preferred Stock Preferred Stock Preferred Stock Common Stock Shares Amount Shares Amount Shares Amount Shares Amount Shares Amount Balance at December 31, 20223,963,963$13,014 5,704,161$25,235 11,370,621$110,791 —— 2,792,929$2 $2,225 $(16)$(72,135)$(69,924)Exercise of common stock options—— —— —— —— 35,552— 31 — — 31 Vesting of restricted common stock awards—— —— —— —— 222,382— — — — — Stock-based compensation expense—— —— —— —— —— 2,259 — — 2,259 Unrealized gain on marketable debt securities—— —— —— —— —— — 16 — 16 Net loss—— —— —— —— —— — — (47,263)(47,263)Balance at December 31, 20233,963,963$13,014 5,704,161$25,235 11,370,621$110,791 ——3,050,863$2 $4,515 $— $(119,398)$(114,881)Issuance of Series C Preferred Stock, net of issuance costs of $528—— — — — — 18,628,970181,328 —— — — — — Issuance of common stock from IPR